bioAffinity Tech(BIAF.US)

Last Updated 19:00:00 ET
longbridge loading

bioAffinity CyPath Lung Test Sales Surge Sharply

Tip Ranks·
US
BIAF
-2.41%
US
BBH
0.00%
US
SBIO
-1.44%
Tip Ranks·
US
BIAF
-2.41%
US
BBH
0.00%
US
SBIO
-1.44%

bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 | BIAF Stock News

StockTitan·
US
BIAF
-2.41%
US
BIAFW
0.00%
US
LABU
-3.30%
StockTitan·
US
BIAF
-2.41%
US
BIAFW
0.00%
US
LABU
-3.30%

bioAffinity Tech | 10-Q: FY2026 Q1 Revenue: USD 1.352 M

Earnings Watch·
US
BIAF
-2.41%
Earnings Watch·
US
BIAF
-2.41%

bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M

businessinsider·
US
BIAF
-2.41%
US
BIAFW
0.00%
US
XBI
-1.09%
businessinsider·
US
BIAF
-2.41%
US
BIAFW
0.00%
US
XBI
-1.09%

bioAffinity Tech | 8-K: FY2026 Q1 Revenue: USD 1.352 M

Earnings Watch·
US
BIAF
-2.41%
Earnings Watch·
US
BIAF
-2.41%

bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung | BIAF Stock News

StockTitan·
US
BIAFW
0.00%
US
BIAF
-2.41%
US
BBH
0.00%
StockTitan·
US
BIAFW
0.00%
US
BIAF
-2.41%
US
BBH
0.00%

bioAffinity Technologies shares are trading higher after the company announced a pilot study evaluating its tests for chronic obstructive pulmonary disease in collaboration with Brooke Army Medical Center.

benzinga_article·
US
BIAFW
0.00%
US
BIAF
-2.41%
US
XBI
-1.09%
benzinga_article·
US
BIAFW
0.00%
US
BIAF
-2.41%
US
XBI
-1.09%

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment | BIAF Stock News

StockTitan·
US
BIAF
-2.41%
US
BIAFW
0.00%
US
PBE
0.00%
StockTitan·
US
BIAF
-2.41%
US
BIAFW
0.00%
US
PBE
0.00%
© 2026 Longbridge｜Disclaimer